NVO vs. RYCEY
NVO (Novo Nordisk A/S) and RYCEY (Rolls-Royce Holdings plc) are both stocks. NVO operates in Drug Manufacturers - General (Healthcare), while RYCEY operates in Aerospace & Defense (Industrials). Over the past 10 years, NVO returned 8.18%/yr vs 7.64%/yr for RYCEY. At a 0.18 correlation, their price movements are largely independent.
Performance
NVO vs. RYCEY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVO achieves a 0.91% return, which is significantly lower than RYCEY's 15.83% return. Over the past 10 years, NVO has outperformed RYCEY with an annualized return of 8.18%, while RYCEY has yielded a comparatively lower 7.64% annualized return.
NVO
- 1D
- -1.41%
- 1M
- 14.86%
- 6M
- -17.63%
- YTD
- 0.91%
- 1Y
- -19.26%
- 3Y*
- -13.51%
- 5Y*
- 4.43%
- 10Y*
- 8.18%
- ALL TIME*
- 14.52%
RYCEY
- 1D
- -1.25%
- 1M
- -3.36%
- 6M
- 4.11%
- YTD
- 15.83%
- 1Y
- 33.75%
- 3Y*
- 111.25%
- 5Y*
- 68.92%
- 10Y*
- 7.64%
- ALL TIME*
- -11.47%
NVO vs. RYCEY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 0.91% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
RYCEY Rolls-Royce Holdings plc | 15.83% | 123.64% | 88.21% | 253.27% | -33.95% | 2.53% | -82.05% | -12.69% | -7.35% | 40.70% |
Correlation
The correlation between NVO and RYCEY is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.24 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.21 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Jul 7, 2014 | 0.18 |
Fundamentals
NVO:
$220.46B
RYCEY:
$150.95B
NVO:
DKK 27.42
RYCEY:
£0.99
NVO:
11.83
RYCEY:
13.56
NVO:
0.51
RYCEY:
0.03
NVO:
4.40
RYCEY:
2.83
NVO:
7.11
RYCEY:
41.62
NVO:
DKK 327.80B
RYCEY:
£40.04B
NVO:
DKK 268.30B
RYCEY:
£10.10B
NVO:
DKK 181.54B
RYCEY:
£8.04B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVO vs. RYCEY — Risk / Return Rank
NVO
RYCEY
NVO vs. RYCEY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Rolls-Royce Holdings plc (RYCEY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVO | RYCEY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.26 | ||
| Sortino ratioReturn per unit of downside risk | -1.69 | ||
| Omega ratioGain probability vs. loss probability | 0.97 | 1.18 | -0.21 |
| Calmar ratioReturn relative to maximum drawdown | -0.39 | 1.56 | -1.95 |
| Martin ratioReturn relative to average drawdown | -0.61 | 4.32 | -4.93 |
Loading charts...
Drawdowns
NVO vs. RYCEY - Drawdown Comparison
The maximum NVO drawdown since its inception was -74.70%, smaller than the maximum RYCEY drawdown of -99.07%. Use the drawdown chart below to compare losses from any high point for NVO and RYCEY.
Loading charts...
Drawdown Indicators
| NVO | RYCEY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.70% | -99.07% | +24.37% |
Max Drawdown (1Y)Largest decline over 1 year | -49.17% | -21.75% | -27.42% |
Max Drawdown (3Y)Largest decline over 3 years | -74.70% | -23.37% | -51.33% |
Max Drawdown (5Y)Largest decline over 5 years | -74.70% | -62.01% | -12.69% |
Max Drawdown (10Y)Largest decline over 10 years | -74.70% | -94.64% | +19.94% |
Current DrawdownCurrent decline from peak | -63.95% | -77.01% | +13.06% |
Average DrawdownAverage peak-to-trough decline | -17.89% | -84.09% | +66.20% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.75% | 7.83% | +23.92% |
Volatility
NVO vs. RYCEY - Volatility Comparison
Novo Nordisk A/S (NVO) has a higher volatility of 9.48% compared to Rolls-Royce Holdings plc (RYCEY) at 8.23%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than RYCEY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVO | RYCEY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.48% | 8.23% | +1.25% |
Volatility (6M)Calculated over the trailing 6-month period | 37.43% | 33.05% | +4.38% |
Volatility (1Y)Calculated over the trailing 1-year period | 51.79% | 38.40% | +13.39% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.58% | 43.23% | -4.65% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.63% | 49.27% | -16.64% |
Dividends
NVO vs. RYCEY - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 3.63%, more than RYCEY's 0.70% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 3.63% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
RYCEY Rolls-Royce Holdings plc | 0.70% | 0.86% | 0.00% | 0.00% | 0.00% | 0.00% | 5.51% | 1.56% | 1.32% | 1.55% | 4.19% | 14.44% |
Financials
NVO vs. RYCEY - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Rolls-Royce Holdings plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVO vs. RYCEY - Profitability Comparison
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
RYCEY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Rolls-Royce Holdings plc reported a gross profit of 3.19B and revenue of 11.64B. Therefore, the gross margin over that period was 27.4%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
RYCEY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Rolls-Royce Holdings plc reported an operating income of 3.23B and revenue of 11.64B, resulting in an operating margin of 27.7%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
RYCEY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Rolls-Royce Holdings plc reported a net income of 1.42B and revenue of 11.64B, resulting in a net margin of 12.2%.
Frequently Asked Questions
NVO and RYCEY have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVO has higher volatility (9.48%) compared to RYCEY (8.23%). In terms of maximum drawdown, NVO dropped -74.70% vs RYCEY's -99.07%.
RYCEY currently has the higher Sharpe Ratio (0.88 vs -0.37), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVO and RYCEY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer